NextPlat Q3 Revenue Misses at $10.5M as Reimbursements and Script Volumes Slip
NXPL has more than doubled off its 52-week low of $3.375.
Summary
NextPlat's Q3 revenue came in at $10.50 million against a single-analyst consensus of $13 million, with the shortfall driven by lower reimbursement rates and reduced retail prescription volumes in the healthcare operations. The loss per share was $0.28. The offsetting story is margin: gross profit rose nearly 35% year over year and gross margin reached 35%, while the net loss narrowed by roughly 66%, helped by a 300% jump in pharmacy contract revenue tied to 340B and a 3% rise in e-commerce revenue on record recurring airtime contracts. Management expects retail prescription volumes to improve starting in Q4 and points to new 340B services contracts lifting revenue in early 2027, plus a nationwide medication fulfillment website launch in Q4. For a company this small, a 19% revenue miss against the only published estimate is the number that matters, and it lands on top of a going-concern doubt and an existing $3.74 million at-the-market program disclosed in prior filings. The lone analyst rating is buy with a $12 median target versus an $8.29 close on November 11.
At the time of this announcement, NXPL was trading at $8.01 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $22.5M. The 52-week trading range was $3.38 to $9.94. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.